25
Participants
Start Date
September 4, 2015
Primary Completion Date
June 19, 2025
Study Completion Date
June 19, 2025
Cisplatin + celecoxib + DC vaccine
Cisplatin 50 mg/m2 by IP once per cycle (21 days) + celecoxib daily 200 mg by mouth daily + intranodal vaccine injections once per cycle
Cisplatin + CKM + Celecoxib + DC Vaccine
Cisplatin 50 mg/m2 by IP once per cycle (21 days) + celecoxib daily 200 mg by mouth daily + IFN by IP once per cycle + rintatolimod 200 mg by IP once per cycle + intranodal vaccine injections once per cycle
UPMC CancerCenter at Magee-Womens Hospital of UPMC, Pittsburgh
Hillman Cancer Center, Pittsburgh
Collaborators (1)
AIM ImmunoTech Inc.
INDUSTRY
National Cancer Institute (NCI)
NIH
University of Pittsburgh
OTHER
Roswell Park Cancer Institute
OTHER